Evidence map›Paper›PMID 35291964›Full record

ArticleBMC psychiatry2022

An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders.

Nadia E Crellin, Stefan Priebe, Nicola Morant, Glyn Lewis, Nick Freemantle, Sonia Johnson, Rob Horne, Vanessa Pinfold, Lyn Kent, Ruth Smith and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Helping people to discontinue antipsychotics: if, when and how.Schizophrenia (Heidelberg, Germany) · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Nadia E CrellinResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, IG3 8XJ, UK. n.crellin@ucl.ac.uk.
Stefan PriebeUnit for Social and Community Psychiatry, Queen Mary University of London, London, E1 4NS, UK.
Nicola MorantDivision of Psychiatry, University College London, London, W1T 7NF, UK.
Glyn LewisDivision of Psychiatry, University College London, London, W1T 7NF, UK.
Nick FreemantleInstitute of Clinical Trials and Methodology, University College London, London, WC1V 6LJ, UK.
Sonia JohnsonDivision of Psychiatry, University College London, London, W1T 7NF, UK.
Rob HorneSchool of Pharmacy, University College London, London, WC1N 1AX, UK.
Vanessa PinfoldThe McPin Foundation, London, SE1 4YR, UK.
Lyn KentIndependent consultant, London, UK.
Ruth SmithIndependent consultant, London, UK.
Katherine DartonIndependent consultant, London, UK.
Ruth E CooperUnit for Social and Community Psychiatry, Queen Mary University of London, London, E1 4NS, UK.
Maria LongResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, IG3 8XJ, UK.
Jemima ThompsonFaculty of Medical Sciences, University College London, London, UK.
Lisa GruenwaldResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, IG3 8XJ, UK.
Robert FreudenthalBarnet Enfield Haringey Mental Health NHS Trust, London, UK.
Jacki L StansfeldResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, IG3 8XJ, UK.
Joanna MoncrieffResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, IG3 8XJ, UK.
University College London · GBGoodmayes Hospital · GBQueen Mary University of London · GBBarnet Enfield and Haringey Mental Health Trust · GBMcPin Foundation · GBNorth East London NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntipsychotic medication can reduce psychotic symptoms and risk of relapse in people with schizophrenia and related disorders, but it is not always effective and adverse effects can be significant. We know little of patients' views about continuing or discontinuing antipsychotic treatment.

aimsTo explore the views of people with schizophrenia and other psychotic disorders about continuing their antipsychotic medication or attempting to reduce or discontinue this medication with clinical support.

methodsWe collected quantitative and qualitative data by conducting semi-structured interviews in London, UK. Factors predicting a desire to discontinue medication were explored. Content analysis of qualitative data was undertaken.

resultsWe interviewed 269 participants. 33% (95% CI, 27 to 39%) were content with taking long-term antipsychotic medication. Others reported they took it reluctantly (19%), accepted it on a temporary basis (24%) or actively disliked it (18%). 31% (95% CI, 25 to 37%) said they would like to try to stop medication with professional support, and 45% (95% CI, 39 to 51%) wanted the opportunity to reduce medication. People who wanted to discontinue had more negative attitudes towards the medication but were otherwise similar to other participants. Wanting to stop or reduce medication was motivated mainly by adverse effects and health concerns. Professional support was identified as potentially helpful to achieve reduction.

conclusionsThis large study reveals that patients are commonly unhappy about the idea of taking antipsychotics on a continuing or life-long basis. Professional support for people who want to try to reduce or stop medication is valued.

Indexed as

Antipsychotic AgentsDrug-Related Side Effects and Adverse ReactionsPsychotic DisordersSchizophreniaHumansRecurrenceWithholding TreatmentAntipsychotic AgentsAntipsychoticsMixed methodsPsychosisSchizophrenia

Identifiers

PMID35291964
PMCPMC8925064
OpenAlexW4221084775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.